UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/450/0.1/19.03.25 | Market Closed - Börse Stuttgart 15:59:55 03/07/2024 BST | ||
| 5.65 EUR | -10.46% |
|
| Current month | -8.58% | ||
| 1 month | -7.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 5.65 | -10.46% |
| 02/07/24 | 6.31 | +4.99% |
| 01/07/24 | 6.01 | -2.75% |
| 28/06/24 | 6.18 | -0.80% |
| 27/06/24 | 6.23 | +0.16% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 03:59 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD441W |
| ISIN | DE000HD441W9 |
| Date issued | 25/03/2024 |
| Strike | 450 $ |
| Maturity | 19/03/2025 (259 Days) |
| Parity | 10 : 1 |
| Emission price | 4.57 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.29 € |
|---|---|
| Lowest since issue | 2.68 € |
| Spread | 0.05 € |
| Spread % | 0.84% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Warrants
- Warrant
